Compare Global X Copper Miners ETF (COPX) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Copper Miners ETF vs Recursion Pharmaceuticals Inc — how do they compare? Global X Copper Miners ETF trades at $85.76 (market cap $7.10B), while Recursion Pharmaceuticals Inc trades at $4.36 (market cap $2.14B). The key difference: Global X Copper Miners ETF is far larger — about 3.3× Recursion Pharmaceuticals Inc's market cap, and Global X Copper Miners ETF is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Global X Copper Miners ETF for 51 Days and Recursion Pharmaceuticals Inc for 23 Days on average.
| COPX | RXRX | |
|---|---|---|
Market Cap | $7.10B | $2.14B |
Volume | 2,871,128 | 30,789,535 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $96.45 | $6.79 |
52-Week Low | $57.43 | $2.84 |
Typical Hold Time | 51 Days | 23 Days |
Enterprise Value | — | $1.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
COPX (Global X Copper Miners ETF) trades at $85.75, up 2.6% with a bearish technical outlook from moving averages. The ETF faces mixed sentiment as copper demand surges due to AI and electrification trends, while miner stocks lag behind metal prices. Recent articles highlight copper's strategic importance but note global surplus concerns and Federal Reserve policy impacts on mining equities.
Outlook hinges on copper price sustainability amid AI-driven demand, though miner valuations remain pressured. Key risks include global copper surplus projections and Fed policy volatility. Opportunities exist from structural copper deficits and operational leverage if metal prices hold near record highs above $6.85/lb (GuruFocus, September 8, 2026).
RXRX trades at $4.36, up 2.11% today, with technical indicators showing a bullish trend. The company reported Q3 2026 revenue of $54 million but continues to post significant losses with a -961.97% net income margin. Recent strategic partnerships with Tempus and Roche are expanding its AI-driven drug pipeline, though the stock faces high short interest and substantial cash burn from operations.
The outlook remains speculative given persistent losses and high valuation multiples (P/S 37.14), but analyst consensus leans positive with 40% buy ratings. Key risks include execution on drug development timelines and dependence on financing activities to fund operations. Upside potential hinges on successful clinical milestones from its expanding pipeline.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Global X Copper Miners ETF
COPX tracks the Solactive Global Copper Miners Total Return Index, providing broad exposure to companies worldwide involved in copper mining, refining, and exploration. It serves as an equity-based alternative to copper futures, offering a leveraged play on copper demand driven by global infrastructure and the clean energy transition.
Read more on COPX →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
